

Financial news for HALO dated on 2020-06-04: Halozyme Announces J&J's Janssen Receives European Marketing Authorization For Subcutaneous DARZALEX Utilizing Halozyme's ENHANZE Technology For The Treatment Of Patients With Multiple Myeloma

Financial news for HALO dated on 2020-05-19: Canaccord Genuity Maintains Buy on Halozyme Therapeutics, Raises Price Target to \$27

Financial news for HALO dated on 2020-05-15: Cramer Weighs In On Ubiquiti, Callaway Golf And More

Financial news for HALO dated on 2020-05-14: Halozyme To Receive \$15 Million Milestone Payment From Janssen

Financial news for HALO dated on 2020-05-13: The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter

Financial news for HALO dated on 2020-05-12: JMP Securities Maintains Market Outperform on Halozyme Therapeutics, Raises Price Target to \$34

Financial news for HALO dated on 2020-05-12: JP Morgan Maintains Overweight on Halozyme Therapeutics, Raises Price Target to \$23

Financial news for HALO dated on 2020-05-12: Stocks That Hit 52-Week Highs On Tuesday

Financial news for HALO dated on 2020-05-12: BMO Capital Maintains Outperform on Halozyme Therapeutics, Raises Price Target to \$35

Financial news for HALO dated on 2020-05-12: The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands \$384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings

Financial news for HALO dated on 2020-05-12: 32 Stocks Moving in Tuesday's Pre-Market Session

Financial news for HALO dated on 2020-05-11: 14 Stocks Moving In Monday's After-Hours Session

Financial news for HALO dated on 2020-05-11: Halozyme Therapeutics shares are trading lower after the company reported worse-than-expected Q1 EPS and sales results.

Financial news for HALO dated on 2020-05-11: Halozyme Sees FY20 GAAP EPS \$0.60-\$0.75, Sales \$230M-\$245M

Financial news for HALO dated on 2020-05-11: Halozyme Therapeutics Q1 EPS \$(0.040) Misses \$(0.020) Estimate, Sales \$25.354M Miss \$42.960M Estimate

Financial news for HALO dated on 2020-05-10: The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight

Financial news for HALO dated on 2020-05-06: EXUMA Biotech Is 'Revolutionizing CAR-T Therapy,' Increasing Patient Access, CEO Says

Financial news for HALO dated on 2020-05-05: The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout

Financial news for HALO dated on 2020-05-04: Halo Labs Experiences Delays In Regulatory Approval For California Dispensary

Financial news for HALO dated on 2020-05-04: Stocks That Hit 52-Week Highs On Monday

Financial news for HALO dated on 2020-05-04: Halozyme Therapeutics shares are continuing higher after Janssen announced FDA approval of a multiple myeloma treatment which uses Halozyme's Enhanze technology.

Financial news for HALO dated on 2020-05-04: Cantor Fitzgerald Reiterates Overweight on Halozyme Therapeutics, Raises Price Target to \$39

Financial news for HALO dated on 2020-05-03: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates

Financial news for HALO dated on 2020-05-01: The Daily Biotech Pulse: Gilead Slips Despite Forecast-Beating Q1, Moderna Partners With Lonza For Coronavirus Vaccine Production, Lyra Therapeutics IPO

Financial news for HALO dated on 2020-04-30: Halozyme Highlights Janssen's Receipt Of CHMP Positive Opinion For DARZALEX Subcutaneous Formulation Utilizing Halozyme's ENHANZE Technology For Patients With Multiple Myeloma

Financial news for HALO dated on 2020-04-29: The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda

Financial news for HALO dated on 2020-04-28: Stocks That Hit 52-Week Highs On Tuesday

Financial news for HALO dated on 2020-04-28: The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update

Financial news for HALO dated on 2020-04-27: Stocks That Hit 52-Week Highs On Monday

Financial news for HALO dated on 2020-04-27: Halozyme shares are trading higher after the company announced Janssen submitted an NDA in Japan for Daratumumab Subcutaneous Formulation using Halozyme's ENHANZE technology.

Financial news for HALO dated on 2020-04-27: Halozyme Announces Janssen Submits NDA In Japan For Daratumumab Subcutaneous Formulation Utilizing Halozyme's ENHANZE(r) Technology For Patients With Multiple Myeloma

Financial news for HALO dated on 2020-04-24: The Daily Biotech Pulse: FDA Approves Sanofi's Meningococcal Vaccine, Pluristem Secures \$54M In Funding For COVID-19 Treatment, Oric Pharma Prices IPO

Financial news for HALO dated on 2020-04-23: Shares of several healthcare companies are trading higher. Movement appears market-related as equities gain amid a rebound in oil prices.

Financial news for HALO dated on 2020-04-23: Stocks That Hit 52-Week Highs On Thursday

Financial news for HALO dated on 2020-04-22: Shares of several healthcare companies are trading higher as equities gain amid oil prices potentially stabilizing following the recent crash.

Financial news for HALO dated on 2020-04-09: Halozyme 13G Filing From Artisan Partners Shows New 10.5% Stake

Financial news for HALO dated on 2020-03-19: The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latest Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection

Financial news for HALO dated on 2020-03-18: The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates

Financial news for HALO dated on 2020-03-17: 10 Small-To-Mid-Cap Biotech Ideas For When The Coronavirus Fades

Financial news for HALO dated on 2020-02-26: The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates

Financial news for HALO dated on 2020-02-25: Barclays Maintains Equal-Weight on Halozyme Therapeutics, Raises Price Target to \$20

Financial news for HALO dated on 2020-02-25: JP Morgan Maintains Overweight on Halozyme Therapeutics, Lowers Price Target to \$22

Financial news for HALO dated on 2020-02-25: Halozyme Announces FDA Has Accepted Biologics License Application For Fixed-Dose Subcutaneous Combination Of Perjeta And Herceptin Using Enhance Technology

Financial news for HALO dated on 2020-02-24: Halozyme Reaffirms FY20 Guidance: GAAP EPS \$0.60-\$0.75, Sales \$230M-\$245M vs \$220.7M Estimate

Financial news for HALO dated on 2020-02-24: Halozyme Therapeutics Q4 EPS \$(0.24) Misses \$(0.15) Estimate, Sales \$53.665M Miss \$56.93M Estimate

Financial news for HALO dated on 2020-02-24: Halozyme Reports CFO Laurie Stelzer Resigned; Elaine Sun Named Replacement

Financial news for HALO dated on 2020-02-23: The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

Financial news for HALO dated on 2020-02-21: Stocks That Hit 52-Week Highs On Friday

Financial news for HALO dated on 2020-02-21: The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion

Financial news for HALO dated on 2020-02-19: The Daily Biotech Pulse: FDA Snub For

Merck, Priority Review For Roche's Tecentriq sBLA

Financial news for HALO dated on 2020-02-18: Stocks That Hit 52-Week Highs On Tuesday

Financial news for HALO dated on 2020-02-06: The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs

Financial news for HALO dated on 2020-02-05: Halozyme Therapeutics shares are trading higher after Piper Sandler upgraded the stock from Neutral to Overweight and raised the price target from \$18 to \$27 per share.

Financial news for HALO dated on 2020-02-05: Stocks That Hit 52-Week Highs On Wednesday

Financial news for HALO dated on 2020-02-05: Benzinga's Top Upgrades, Downgrades For February 5, 2020

Financial news for HALO dated on 2020-02-05: Piper Sandler Upgrades Halozyme Therapeutics to Overweight, Raises Price Target to \$27

Financial news for HALO dated on 2020-01-27: 10 Biggest Price Target Changes For Monday

Financial news for HALO dated on 2020-01-27: Cantor Fitzgerald Maintains Overweight on Halozyme Therapeutics, Raises Price Target to \$35

Financial news for HALO dated on 2020-01-17: The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares

Financial news for HALO dated on 2020-01-16: Stocks That Hit 52-Week Highs On Thursday

Financial news for HALO dated on 2020-01-16: The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics

Financial news for HALO dated on 2020-01-15: Stocks That Hit 52-Week Highs On Wednesday

Financial news for HALO dated on 2020-01-15: The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance

Financial news for HALO dated on 2020-01-14: Halozyme Therapeutics shares are trading higher after the company issued FY20 sales guidance above analyst estimates. The company also added \$150 million to its buyback.

Financial news for HALO dated on 2020-01-14: Halozyme Adds \$150M to Buyback

Financial news for HALO dated on 2020-01-14: Halozyme Sees FY20 Sales \$230M-\$245M vs \$227.01M Est.

Financial news for HALO dated on 2020-01-14: Halozyme Provides 2020 Business Update And Financial Guidance

Financial news for HALO dated on 2020-01-09: 10 Biggest Price Target Changes For Thursday

Financial news for HALO dated on 2020-01-09: Benzinga's Top Upgrades, Downgrades For January 9, 2020

Financial news for HALO dated on 2020-01-09: Halozyme Therapeutics shares are trading higher after BMO Capital upgraded the stock from Market Perform to Outperform and raised the price target from \$17 to \$24 per share.

Financial news for HALO dated on 2020-01-09: BMO Capital Upgrades Halozyme Therapeutics to Outperform, Raises Price Target to \$24

Financial news for HALO dated on 2020-01-08: UPDATE: Goldman On Halozyme Notes Co. 'is further de-risked, in that Enhance is a proven technology: HALO has nine partnerships with top biopharma (including Roche, JNJ, ARGX, and ALXN) for it, and Enhance is already used in three approved products'

Financial news for HALO dated on 2020-01-08: UPDATE: Goldman Initiates Halozyme Therapeutics With Buy, \$24 Target Notes 'Moving away from its own drugs, a newer, simpler and low(er) risk biotech story emerges'

Financial news for HALO dated on 2020-01-08: Halozyme Therapeutics shares are trading higher after Goldman Sachs initiated coverage on the stock with a Buy rating and

announced a \$24 price target.

Financial news for HALO dated on 2020-01-08: Goldman Sachs Initiates Coverage On Halozyyme Therapeutics with Buy Rating, Announces \$24 Price Target

Financial news for HALO dated on 2019-12-29: Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus

Financial news for HALO dated on 2019-12-12: Data From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta(r) And Herceptin(r) Using Halozyyme's ENHANZE(r) Drug Delivery Technology To Be Presented At San Antonio Breast Cancer Symposium

Financial news for HALO dated on 2019-11-26: The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug

Financial news for HALO dated on 2019-11-25: Stocks That Hit 52-Week Highs On Monday

Financial news for HALO dated on 2019-11-21: The Daily Biotech Pulse: Patent Win For Collectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon

Financial news for HALO dated on 2019-11-20: Stocks That Hit 52-Week Highs On Wednesday

Financial news for HALO dated on 2019-11-20: Cantor Fitzgerald Reiterates Overweight on Halozyyme Therapeutics, Raises Price Target to \$27

Financial news for HALO dated on 2019-11-20: The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data

Financial news for HALO dated on 2019-11-19: Stocks That Hit 52-Week Highs On Tuesday

Financial news for HALO dated on 2019-11-15: Stocks That Hit 52-Week Highs On Friday

Financial news for HALO dated on 2019-11-15: The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval

Financial news for HALO dated on 2019-11-14: Halozyyme Therapeutics shares are trading higher despite pricing its private offering of \$400 million of convertible senior notes. The stock is trading on approximately 12X higher-than-average volume.

Financial news for HALO dated on 2019-11-14: Stocks That Hit 52-Week Highs On Thursday

Financial news for HALO dated on 2019-11-14: The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing

Financial news for HALO dated on 2019-11-13: BMO Capital Maintains Market Perform on Halozyyme Therapeutics, Raises Price Target to \$17

Financial news for HALO dated on 2019-11-13: JP Morgan Maintains Overweight on Halozyyme Therapeutics, Raises Price Target to \$23

Financial news for HALO dated on 2019-11-12: Halozyyme Therapeutics Q3 EPS \$(0.17) Misses \$(0.12) Estimate, Sales \$46.23M Miss \$54.81M Estimate

Financial news for HALO dated on 2019-11-12: The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat

Financial news for HALO dated on 2019-11-05: Benzinga's Top Upgrades, Downgrades For November 5, 2019

Financial news for HALO dated on 2019-11-05: Barclays Upgrades Halozyyme Therapeutics to Equal-Weight, Lowers Price Target to \$16

Financial news for HALO dated on 2019-11-04: Halozyyme Scraps Oncology Program Following Failed Study, Charts Out Profitability Plan

Financial news for HALO dated on 2019-11-04: Halozyyme's Phase 3 Study of PEGPH20 Misses its Primary Endpoint, Company to Halt Oncology Operations in Effort to Achieve \$130M to \$140M of Annual Cost Savings

Financial news for HALO dated on 2019-09-26: Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.

Financial news for HALO dated on 2019-09-24: Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.

Financial news for HALO dated on 2019-09-13: The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study, Catalyst Shelves Offering Plans

Financial news for HALO dated on 2019-09-13: Halozyme Announces Positive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta(r) And Herceptin(r) Using Halozyme's Enhanze(r) Drug Delivery Technology

Financial news for HALO dated on 2019-08-06: Halozyme Therapeutics Q2 EPS \$(0.10) Beats \$(0.14) Estimate, Sales \$39.148M Miss \$42.76M Estimate

Financial news for HALO dated on 2019-08-06: The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering

Financial news for HALO dated on 2019-07-19: Halozyme Reports J&J's Janssen Submitted Extension Application To EMA For Subcutaneous Formulation Of DARZALEX Utilizing ENHANZE Technology

Financial news for HALO dated on 2019-07-17: Halozyme Announces First Clinical Dosing In argenx's Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE Drug Delivery Technology

Financial news for HALO dated on 2019-07-12: Halozyme Therapeutics Reports J&J's Janssen Submitted Biologics License Application To FDA For Subcutaneous Delivery Of DARZALEX For Patients With Multiple Myeloma

Financial news for HALO dated on 2019-06-25: Halozyme Announces CRADA With National Institute Of Allergy And Infectious Diseases For Use Of ENHANZE Drug Delivery Technology

Financial news for HALO dated on 2019-05-22: The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study

Financial news for HALO dated on 2019-05-22: Halozyme Announces argenx Has Selected Second Target Under ENHANZE Technology Collaboration And License Agreement; Triggers \$10M Milestone Payment

Financial news for HALO dated on 2019-05-07: Halozyme Therapeutics Guides FY19 Revenues Of \$205M-\$215M Vs. \$209.09M Estimate

Financial news for HALO dated on 2019-05-07: Halozyme Therapeutics Q1 EPS \$0.01, Inline, Sales \$56.949M Miss \$67.8M Estimate

Financial news for HALO dated on 2019-05-07: The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex

Financial news for HALO dated on 2019-04-30: Shares of several healthcare companies are trading lower on continued uncertainty over healthcare policy as well as concerns over the medicare-for-all proposals among 2020 candidates.

Financial news for HALO dated on 2019-02-28: Halozyme Reports FDA Approval Of Herceptin Hylecta

Financial news for HALO dated on 2019-02-21: Halozyme Therapeutics Sees FY19 Sales \$205M-\$215M vs \$168.78M Est.

Financial news for HALO dated on 2019-02-21: Halozyme Therapeutics Q4 EPS \$(0.01) Beats \$(0.03) Estimate, Sales \$60.2M Beat \$59.94M Estimate

Financial news for HALO dated on 2019-02-21: The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan

Financial news for HALO dated on 2019-02-15: The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings

Financial news for HALO dated on 2019-02-04: Halozyme Therapeutics shares are trading higher after the company announced it entered a global collaboration and license agreement with Argenx for the use of ENHANZE Technology.

Financial news for HALO dated on 2019-02-04: Argenx, Halozyme Enter Global Collaboration and License Agreement for ENHANZE Technology

Financial news for HALO dated on 2019-01-09: Halozyme Provides 2019 Pipeline Update At 37th Annual JP Morgan Healthcare Conference

Financial news for HALO dated on 2019-01-09: Halozyme Sees FY19 Sales \$175M-\$185M vs \$152.57M Est.

Financial news for HALO dated on 2018-12-20: The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum

Financial news for HALO dated on 2018-11-28: 48 Biggest Movers From Yesterday

Financial news for HALO dated on 2018-11-27: 38 Stocks Moving In Tuesday's Mid-Day Session

Financial news for HALO dated on 2018-11-27: Halozyme Therapeutics shares are trading down 7.2% after the company agreed to change the efficacy endpoint measure in its Phase 3 clinical trial of PEGPH20.

Financial news for HALO dated on 2018-11-27: 32 Stocks Moving In Tuesday's Pre-Market Session

Financial news for HALO dated on 2018-11-27: The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial

Financial news for HALO dated on 2018-11-26: Halozyme shares down 16.6% as company adjusted the qualification for its endpoint of its HALO-301 trial to a single primary endpoint of overall survival

Financial news for HALO dated on 2018-11-26: Halozyme Shares Resume Trade, Down 3%

Financial news for HALO dated on 2018-11-26: Halozyme Shares To Resume Trade At 4:35 p.m. EST

Financial news for HALO dated on 2018-11-26: Halozyme Changes Primary Endpoint In HALO-301 Trial To Single Primary Endpoint Of Overall Survival

Financial news for HALO dated on 2018-11-26: Halozyme Therapeutics Shares Halted News Pending

Financial news for HALO dated on 2018-11-06: Halozyme Therapeutics Raises FY18 Sales Guidance From \$125M-\$135M To \$150M-\$160M vs \$126.97M Est.; NOTE: Guidance Raise Driven By \$25M Upfront Payment From Roche ENHANZE Agreement

Financial news for HALO dated on 2018-11-06: Halozyme Therapeutics, Inc. Q3 EPS \$(0.19) Beats \$(0.23) Estimate, Sales \$25.56M Miss \$30.42M Estimate

Financial news for HALO dated on 2018-11-06: A Preview Of Halozyme Therapeutics Q3 Earnings

Financial news for HALO dated on 2018-11-06: The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering

Financial news for HALO dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for HALO dated on 2018-10-30: Halozyme Licenses New ENHANZE Targets For \$25 Million Upfront Payment And Up To \$265M In Future Milestones And Royalties

Financial news for HALO dated on 2018-10-25: Halozyme Announces First Clinical Dosing In Bristol-Myers Squibb's Phase 1 Trial Of BMS-986179 With Enhance Technology; Initiation Of Study Triggered \$5M Milestone Payment To Halozyme

Financial news for HALO dated on 2018-10-25: The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price

Financial news for HALO dated on 2018-10-24: Stocks Which Set New 52-Week Low Yesterday, October 23rd

Financial news for HALO dated on 2018-10-23: Stocks Which Set New 52-Week Low Yesterday, October 22nd

Financial news for HALO dated on 2018-10-23: The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares

Financial news for HALO dated on 2018-10-09: 26 Stocks Moving In Tuesday's Pre-Market Session

Financial news for HALO dated on 2018-09-17: Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab From Health Canada

Financial news for HALO dated on 2018-08-23: Cantor Fitzgerald Initiates Coverage On Halozyme Therapeutics with Overweight Rating, Announces \$27 Price Target

Financial news for HALO dated on 2018-08-07: Halozyme Therapeutics Q2 EPS \$(0.16) Beats \$(0.22) Estimate, Sales \$35.2M Beat \$30.09M Estimate

Financial news for HALO dated on 2018-08-07: The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel

Financial news for HALO dated on 2018-07-26: Phase 3 Study Of Roche's Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE Technology

Financial news for HALO dated on 2018-07-11: Halozyme Therapeutics Reports FDA Acceptance Of Biologics License Application For Subcutaneous Formulation Of Herceptin

Financial news for HALO dated on 2018-05-14: 50 Biggest Movers From Friday

Financial news for HALO dated on 2018-05-11: 38 Stocks Moving In Friday's Mid-Day Session

Financial news for HALO dated on 2018-05-11: Benzinga's Top Upgrades, Downgrades For May 11, 2018

Financial news for HALO dated on 2018-05-11: Benzinga's Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy's Revenue Miss, FDA Warns E-Liquid Makers Again

Financial news for HALO dated on 2018-05-11: 22 Stocks Moving In Friday's Pre-Market Session

Financial news for HALO dated on 2018-05-11: Barclays Downgrades Halozyme Therapeutics to Underweight

Financial news for HALO dated on 2018-05-10: Halozyme Therapeutics Reaffirms FY18 Outlook; Sees Sales \$115M-\$125M vs \$137.01M Est.

Financial news for HALO dated on 2018-05-10: Halozyme Therapeutics Q1 EPS \$(0.19) Beats \$(0.22) Estimate, Sales \$30.872M Miss \$31.43M Estimate

Financial news for HALO dated on 2018-05-10: Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results

Financial news for HALO dated on 2018-05-06: The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Financial news for HALO dated on 2018-04-23: 24 Stocks Moving In Monday's Pre-Market Session

Financial news for HALO dated on 2018-02-20: Halozyme Reaffirms FY18 Sales Outlook: \$115M-\$125M vs \$139.5M Est.

Financial news for HALO dated on 2018-02-20: Halozyme Therapeutics Reports Q4 EPS \$0.85 vs \$0.72 Est., Sales \$189.6M vs \$165.2M Est.

Financial news for HALO dated on 2018-02-20: Halozyme Option Alert: Mar 16 \$18 Calls Sweep (2) at the Bid: 600 @ \$1.301 vs 1865 OI; Earnings 2/20 After Close Ref=\$18.53

Financial news for HALO dated on 2018-02-19: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Financial news for HALO dated on 2018-01-24: 32 Stocks Moving In Wednesday's Mid-Day Session

Financial news for HALO dated on 2018-01-24: Benzinga's Top Upgrades, Downgrades For January 24, 2018

Financial news for HALO dated on 2018-01-24: Goldman Sachs Initiates Coverage On Halozyme Therapeutics with Neutral Rating, Announces \$20.00 Price Target

Financial news for HALO dated on 2018-01-18: 44 Biggest Movers From Yesterday

Financial news for HALO dated on 2018-01-17: Halozyme Therapeutics Shares Down 11.32% Following Release Of SWOG Abstract Suggesting The Co's PEGPH20 In Combination With mFFOX Shows No Benefit And Appears To Be Detrimental; Hearing Deutsche Bank Lowered Price Target From \$21 to \$19 In Response

Financial news for HALO dated on 2018-01-17: 38 Stocks Moving In Wednesday's Mid-Day Session

Financial news for HALO dated on 2018-01-17: 30 Stocks Moving In Wednesday's Pre-

## Market Session

Financial news for HALO dated on 2018-01-10: Halozyme Late Tuesday Announced It Sees 25-30% Royalty Revenue Growth In 2018, Potential For Royalty Revenue To Reach ~\$1B In 2027

Financial news for HALO dated on 2017-12-28: Halozyme Option Alert: Jan 19 \$20 Puts Sweep (30) at the Ask: 504 @ \$0.801 vs 5597 OI; Ref=\$20.6141

Financial news for HALO dated on 2017-12-19: Lightning Round: Jim Cramer Weighs In On Groupon, First Solar, Roku, And More

Financial news for HALO dated on 2017-12-07: Alexion and Halozyme Enter License Agreement for ENHANZE, Halozyme to Receive a \$40M Upfront Payment

Financial news for HALO dated on 2017-11-22: Barclays Assumes Halozyme Therapeutics at Equal-Weight, Announces price target \$19.00

Financial news for HALO dated on 2017-11-10: Halozyme Option Alert: Jan 19 \$19 Calls at the Bid: 1000 @ \$1.2 vs 1374 OI; Ref=\$19.03

Financial news for HALO dated on 2017-11-09: Lightning Round: Jim Cramer Advises His Viewers On Gilead, Exxon Mobil And More

Financial news for HALO dated on 2017-11-08: Halozyme Therapeutics Shares Up 13.12% After Co. Tuesday Reported Impressive Q3 Beat and FY17 Guidance Raise

Financial news for HALO dated on 2017-11-07: Halozyme Raises FY17 Sales Guidance From \$245M-\$260M To \$265M-\$280M vs \$259M Est.

Financial news for HALO dated on 2017-11-07: Halozyme Reports Q3 EPS \$0.02 vs \$(0.23) In Same Qtr. Last Year, Sales \$63.7M vs \$59M Est.

Financial news for HALO dated on 2017-10-31: UPDATE: Halozyme Will Receive \$15M Milestone Payment From J&J's Janssen Following Dosing Of 3rd Patient In Phase 3 Trial

Financial news for HALO dated on 2017-10-31: Halozyme Therapeutics Reports Phase 3 Study Of Subcutaneous Daratumumab Initiated Using Co.'s ENHANZE Technology

Financial news for HALO dated on 2017-10-24: Halozyme Reports First Gastric Cancer Patient Dosed In Trial Collaboration Evaluating Co.'s PEGPH20 In Combo With Anti-PDL1 Immunotherapy

Financial news for HALO dated on 2017-10-16: 10 Stocks Moving In Monday's After-Hours Session

Financial news for HALO dated on 2017-10-16: Halozyme Initiates Trial of PEGPH20

Financial news for HALO dated on 2017-09-15: Watch These 5 Huge Call Purchases In Friday Trade

Financial news for HALO dated on 2017-09-14: Benzinga's Option Alert Recap From September 14

Financial news for HALO dated on 2017-09-14: Halozyme Option Alert: Jan 19 \$16 Calls at the Bid: 919 @ \$1.15 vs 314 OI; Ref=\$15.6

Financial news for HALO dated on 2017-09-14: Mid-Afternoon Market Update: Dow Gains 50 Points; Glaukos Shares Slide

Financial news for HALO dated on 2017-09-14: 15 Biggest Mid-Day Gainers For Thursday

Financial news for HALO dated on 2017-09-14: Mid-Day Market Update: Crude Oil Up Over 2%; Summit Therapeutics Shares Plunge

Financial news for HALO dated on 2017-09-14: Mid-Morning Market Update: Markets Mostly Lower; United Natural Foods Profit Beats Expectations

Financial news for HALO dated on 2017-09-14: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for HALO dated on 2017-09-14: Halozyme Therapeutics Raises fy Sales Guidance from \$115.0M-130.0M to \$245.0M-260.0M vs \$131.90M Est

Financial news for HALO dated on 2017-09-14: Halozyme Announces the Licensing of its ENHANZE to Roche for \$30M Upfront

Financial news for HALO dated on 2017-09-14: Bristol-Myers and Halozyme Enter Collaboration and License Agreement Using Halozyme's ENHANZE, Halozyme to Receive



\$105M Upfront

Financial news for HALO dated on 2017-08-17: Secondary Offering Lockup Expirations Today From Halozyme Therapeutics, Indentiv, and Harte Hanks

Financial news for HALO dated on 2017-08-08: Halozyme Reports Q2 Loss/Share \$(0.23) vs. \$(0.24) Est., Sales \$33.8M vs. \$31.76M Est.

Financial news for HALO dated on 2017-07-13: Halozyme Report Start Of Multi-Arm Clinical Trial Evaluating PEGPH20 In Combination With atezolizumab

Financial news for HALO dated on 2017-06-28: Halozyme Therapeutics New Safety Data Show Bleeding Events Balanced Between 2 Arms After Introduction of Low Molecular Weight Heparin In Stage 2 of Study

Financial news for HALO dated on 2017-06-15: Benzinga's Option Alert Recap From June 15

Financial news for HALO dated on 2017-06-15: Option Alert: Halozyme Jul 15.0 Calls Sweep: 1000 @ ASK \$0.15: 1054 traded vs 320 OI: Earnings 8/8 After Close (est) \$12.88 Ref

Financial news for HALO dated on 2017-06-04: Halozyme Announces Encouraging Phase 2 Data In Advanced Pancreas Cancer Featured in Oral Presentation #ASCO17

Financial news for HALO dated on 2017-05-19: Mid-Afternoon Market Update: Dow Climbs 150 Points; Foot Locker Shares Drop On Earnings Miss

Financial news for HALO dated on 2017-05-19: 10 Biggest Mid-Day Losers For Friday

Financial news for HALO dated on 2017-05-19: Mid-Day Market Update: Crude Oil Up 2%; Halozyme Therapeutics Shares Plunge

Financial news for HALO dated on 2017-05-19: Mid-Morning Market Update: Markets Open Higher; Deere Earnings Beat Views

Financial news for HALO dated on 2017-05-19: Halozyme Shares Move to Premarket High of \$13.05; Co Priced 10M Share Offering @\$12.50/Share

Financial news for HALO dated on 2017-05-19: 22 Stocks Moving In Friday's Pre-Market Session

Financial news for HALO dated on 2017-05-18: Halozyme Therapeutics Reports \$100M Offering Common Stock

Financial news for HALO dated on 2017-05-17: Halozyme Says HALO-202 Study Met Primary, Key Secondary Endpoints, Showed Statistically Significant Improvement in Progression-Free Survival in Patients with High Levels of Hyaluronan

Financial news for HALO dated on 2017-05-09: Halozyme Sees FY17 Sales \$115-\$130M vs \$132M Est.

Financial news for HALO dated on 2017-05-09: Halozyme Reports Q1 EPS \$(0.26) vs \$(0.25) Est., Sales \$29.6M vs \$30.8M Est.

Financial news for HALO dated on 2017-04-17: Benzinga's Top Upgrades, Downgrades For April 17, 2017

Financial news for HALO dated on 2017-04-17: BMO Capital Initiates Coverage On Halozyme Therapeutics with Market Perform Rating, Announces \$14.00 Price Target

Financial news for HALO dated on 2017-04-03: Halozyme Reports PEGPH20 Increases Immune Response, Effectiveness of Immunotherapies in Preclinical Cancer Models

Financial news for HALO dated on 2017-03-30: 15 Biggest Mid-Day Losers For Thursday

Financial news for HALO dated on 2017-03-30: Halozyme Therapeutics Falls After Group Clinical Study Closed To Enrollment

Financial news for HALO dated on 2017-03-30: Halozyme Therapeutics Says SWOG Collaborative Group Clinical Study Temporarily Closed To Enrollment,

Financial news for HALO dated on 2017-03-29: Halozyme Therapeutics Reports FDA Panel Provided Unanimous Recommendation for Rituximab Coformulated with Halozyme's Enhance Technology

Financial news for HALO dated on 2017-02-28: Halozyme Reports Q4 EPS \$(0.21) vs. \$(0.28) Est., Sales \$39M vs. \$38.3M

Financial news for HALO dated on 2017-02-24: Benzinga's Option Alert Recap From February 24

Financial news for HALO dated on 2017-02-24: Option Alert: Halozyme Jun 17.0 Calls Sweep: 500 @ ASK \$0.30: 500 traded vs 2368 OI: Earnings 2/28 After Close \$12.00 Ref

Financial news for HALO dated on 2017-02-13: UPDATE: MabVax Says MVT-5873 Demonstrated Improvement in Accumulation on Tumors in An Animal Model of Pancreatic Cancer

Financial news for HALO dated on 2017-02-13: MabVax Therapeutics Reports Studies Lead Investigational MVT-5873 with Halozyme PEGPH20

Financial news for HALO dated on 2017-02-06: First Eagle Investment Management Reports 5.94% Stake In Halozyme Therapeutics

Financial news for HALO dated on 2017-01-11: Option Alert: Halozyme Mar 12.0 Call: 3838 @ BID @ \$1.26; \$13.94 Ref

Financial news for HALO dated on 2017-01-11: Option Alert: Halozyme Jan 11.0 Puts Sweep: 510 @ ASK \$0.10: 510 traded vs 1968 OI: Earnings 2/27 After Close (est) \$12.51 Ref

Financial news for HALO dated on 2017-01-10: 15 Biggest Mid-Day Losers For Tuesday

Financial news for HALO dated on 2017-01-10: 20 Stocks Moving In Tuesday's Pre-Market Session

Financial news for HALO dated on 2017-01-09: Halozyme Says Expects to Make Continued Progress Showing Pan-Tumor Potential of PEGPH20, Focus on Near-Term Catalysts in ENHANZE Platform

Financial news for HALO dated on 2017-01-09: Halozyme Sees FY17 Sales \$115M-\$130M vs \$146M Est.

Financial news for HALO dated on 2017-01-05: 15 Biggest Mid-Day Gainers For Thursday

Financial news for HALO dated on 2017-01-05: Halozyme Surrenders Most Of Its Pre-Market Gains

Financial news for HALO dated on 2017-01-05: Halozyme Achieves Endpoint In Pancreatic Cancer Study, But Not Everyone Is Bullish

Financial news for HALO dated on 2017-01-05: Adam Feuerstein Tweets: And we wonder why biotech industry has poor reputation for transparency and honest disclosure of data. Stop the nonsense, \$HALO.

Financial news for HALO dated on 2017-01-05: Adam Feuerstein Tweets: \$HALO Shameful conduct this morning. Press release cherry picks single, most positive data point, omits everything else less so.

Financial news for HALO dated on 2017-01-05: Adam Feuerstein @adamfeuerstein Tweet: \$HALO stage 1 data, stage 2 data, stage 1/2 combined, HA high, HA low, ITT, evaluable, etc. Throw all against wall, hope something sticks.

Financial news for HALO dated on 2017-01-05: 25 Stocks Moving In Thursday's Pre-Market Session

Financial news for HALO dated on 2017-01-05: Adam Feuerstein Tweets: \$HALO data are muddled mess. Listening to the call.

Financial news for HALO dated on 2017-01-05: Adam Feuerstein Tweets: \$HALO followers, did you read the PR closely? Seems like they're only reporting positive results from a subset of pancreatic cancer pats.

Financial news for HALO dated on 2017-01-05: Halozyme +54% Premarket @\$16.45; Co Announced Phase 2 Study In Advanced Pancreas Cancer Meets Key Endpoints

Financial news for HALO dated on 2017-01-05: Halozyme Achieves Endpoint in Phase 2 Study In Advanced Pancreas Cancer

Financial news for HALO dated on 2017-01-05: Halozyme Phase 2 Study Meets Primary Endpoints

Financial news for HALO dated on 2016-12-21: Watch These 4 Huge Put Purchases In Wednesday Trade

Financial news for HALO dated on 2016-12-20: Option Alert: Halozyme Jan 10.0 Puts

Sweep: 726 @ ASK \$0.799: 3305 traded vs 564 OI: Earnings 2/27 After Close (est) \$11.36 Ref

Financial news for HALO dated on 2016-11-21: Halozyme Reports AbbVie Discontinues Development Program Using ENHANZE Platform, Will Continue To Identify Additional Targets Under 2015 Partnership And Licensing Agreement

Financial news for HALO dated on 2016-11-10: Halozyme Reports Broad Clinical Collaboration Deal to Evaluate PEGPH20, Tecentriq in Up to Eight Tumor Types

Financial news for HALO dated on 2016-11-07: Halozyme Therapeutics Sees FY16 Rev. \$145-\$150M vs. Est. \$148.8M

Financial news for HALO dated on 2016-11-07: Halozyme Therapeutics Reports Q3 EPS \$(0.23) vs. Est. \$(0.27), Rev. \$31.9M vs. Est. \$33.8M

Financial news for HALO dated on 2016-11-04: Watch These 5 Huge Call Purchases In Friday Trade

Financial news for HALO dated on 2016-11-03: Option Alert: HALO Jan17 10.0 Calls Sweep: 1342 @ ASK \$1.20: 1348 traded vs 5832 OI: Earnings 11/7 After Close \$8.48 Ref

Financial news for HALO dated on 2016-11-03: Benzinga's Top Initiations

Financial news for HALO dated on 2016-11-03: FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab

Financial news for HALO dated on 2016-11-03: Deutsche Bank Initiates Coverage On Halozyme Therapeutics, Inc. - Common Stock at Buy

Financial news for HALO dated on 2016-10-31: 10 Stocks That Plummeted The Past Three Days On Increasing Volume

Financial news for HALO dated on 2016-10-17: Option Alert: HALO Nov \$13 Call Sweep; 755 @ Ask @\$0.23

Financial news for HALO dated on 2016-10-17: Watch These 5 Huge Put Purchases In Monday Trade

Financial news for HALO dated on 2016-10-14: Option Alert: HALO Nov16 9.0 Puts: 3000 @ ASK \$0.50: 3000 traded vs 15 OI: Earnings 11/14 \$10.32 Ref

Financial news for HALO dated on 2016-10-04: Halozyme Drug PEGPH20 Included In Precision Promise Pancreatic Cancer Study

Financial news for HALO dated on 2016-09-22: 25 Stocks Which Rallied Four Days, Then Sold Off Yesterday

Financial news for HALO dated on 2016-09-01: Halozyme Names Mark Gergen COO

Financial news for HALO dated on 2016-08-09: Halozyme Raises FY16 Outlook: Sales from \$130M-\$145M to \$140M-\$150M vs \$138.7M Est., Cash Flow from \$45M-\$65M to \$65M-\$85M

Financial news for HALO dated on 2016-08-09: Halozyme Q2 EPS \$(0.21) vs \$(0.27) Est., Sales \$33.3M vs \$29.9M Est.

Financial news for HALO dated on 2016-07-25: Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Trial With KEYTRUDA

Financial news for HALO dated on 2016-06-08: UPDATE: Halozyme Raises '16 Year-End Cash Balance Outlook from \$150M-\$170M to \$170M-\$190M

Financial news for HALO dated on 2016-06-08: Halozyme Reports Deal to Refinance Debt, Raises '16 Outlook for Year-End Cash Balance

Financial news for HALO dated on 2016-06-06: Mid-Morning Market Update: Markets Open Higher; Devon Energy To Sell Non-Core Upstream Assets For Around \$1 Billion

Financial news for HALO dated on 2016-06-04: Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20 at #ASCO16

Financial news for HALO dated on 2016-05-09: Halozyme Rasises FY 2016 Guidance; Sees Revenue \$130M to \$145M vs \$127.89M est

Financial news for HALO dated on 2016-05-09: Halozyme Q1 EPS (\$0.16) vs (\$0.20) est, Revenue \$42.50M vs \$26.65M, May Not Compare

Financial news for HALO dated on 2016-03-16: Halozyme Reports Dosing of First Patient in Phase 3 Trial of PEGPH20 in Combo with ABRAXANE, Gemcitabine

Financial news for HALO dated on 2016-03-01: Mid-Morning Market Update: Markets Open Higher; Dollar Tree Misses Q4 Views

Financial news for HALO dated on 2016-03-01: 10 Stocks Moving In Tuesday's Pre-Market Session

Financial news for HALO dated on 2016-02-29: 7 Stocks Moving In Today's After-Hours Session

Financial news for HALO dated on 2016-02-29: Halozyme Sees FY Revenue \$110M to \$125M vs \$120.2M est

Financial news for HALO dated on 2016-02-29: Halozyme Q4 EPS \$0.03 vs (\$0.08) est, Revenue \$52.2M vs \$42.1M est

Financial news for HALO dated on 2016-02-29: Earnings Scheduled For February 29, 2016

Financial news for HALO dated on 2016-02-24: CORRECTION: Barclays Maintains Overweight on Halozyme Therapeutics, Lowers PT to \$16.00

Financial news for HALO dated on 2016-02-24: Barclays Maintains Overweight on Halozyme Therapeutics, Lowers PT to \$16.00

Financial news for HALO dated on 2016-02-01: Benzinga's Top Initiations

Financial news for HALO dated on 2016-02-01: Canaccord Genuity Initiates Coverage on Halozyme Therapeutics at Buy

Financial news for HALO dated on 2016-01-21: Halozyme Confirms \$5 Million Milestone Payment From AbbVie

Financial news for HALO dated on 2016-01-21: Halozyme Reports Initial Dosing Of Adalimumab Using ENHANCE Technology, Triggers \$5M Payment To Halozyme From Abbvie

Financial news for HALO dated on 2016-01-14: Mid-Morning Market Update: Markets Down; JPMorgan Beats Q4 Expectations

Financial news for HALO dated on 2016-01-13: Mid-Afternoon Market Update: Dow Tumbles Over 300 Points; Cyberark Shares Gain Following Merger Chatter

Financial news for HALO dated on 2016-01-11: Halozyme Sees FY16 Rev. \$110-\$125M vs. Est. \$117.9M

Financial news for HALO dated on 2016-01-04: Halozyme Enters \$150M Non-Dilutive Royalty-Backed Debt Financing Agreement With Roche & Baxalta

Financial news for HALO dated on 2015-12-21: UPDATE: Halozyme Says Will Receive Initial \$25M Payment, Followed by Milestone Payments of Up to \$160M for Each of Up to Five Collab Targets

Financial news for HALO dated on 2015-12-21: Halozyme Reports Entering of Global Collab, Licensing Deal with Lilly

Financial news for HALO dated on 2015-12-09: Halozyme Therapeutics, Eisai To Give Data Evaluating Antitumor Effects Of PEGPH20 With Eribulin Mesylate In Pre-Clinical Breast Cancer Models

Financial news for HALO dated on 2015-12-04: Benzinga's Top #PreMarket Gainers

Financial news for HALO dated on 2015-12-04: Wells Fargo Initiates Coverage on Halozyme Therapeutics at Outperform

Financial news for HALO dated on 2015-11-18: Halozyme Shares Recently Make Parabolic Move, Spiking to High at \$17.70; Shares Up ~8.7% to \$17 At Last Check

Financial news for HALO dated on 2015-11-18: Benzinga's Top Initiations

Financial news for HALO dated on 2015-11-18: Citigroup Initiates Coverage on Halozyme Therapeutics at Buy, Announces \$25.00 PT

Financial news for HALO dated on 2015-11-17: Halozyme To Open New San Francisco Office, Expects To Recruit Talent To Help Commercialize New PEGPH20 Drug

Financial news for HALO dated on 2015-11-10: Halozyme Spikes Higher

Financial news for HALO dated on 2015-11-10: Shares Of Halo Spiking

Financial news for HALO dated on 2015-11-09: Halozyme Sees FY15 Rev. \$110-\$115M vs. Est. \$111.21M

Financial news for HALO dated on 2015-11-09: Halozyme Reports Q3 EPS \$(0.19) vs. Est. \$(0.16), Rev. \$20.8M vs. Est. \$24.01M

Financial news for HALO dated on 2015-11-05: First Patient Dosed in Clinical Trial of Halozyme Investigational Drug PEGPH20 in Combination With Merck Immuno-oncology Drug KEYTRUDA

Financial news for HALO dated on 2015-11-04: Shares of Halozyme Spike to Session High \$17.74 Over Last Min; Price Seems to Be Breaking Out Higher Following Consolidation Phase Near \$17.25 Support Level

Financial news for HALO dated on 2015-11-04: Halozyme Reports First Clinical Dosing Of Janssen's Daratumumab Using ENHANZE Technology

Financial news for HALO dated on 2015-10-29: Halozyme Reports First Clinical Dosing of Pfizer's Rivipansel Using Enhance Technology

Financial news for HALO dated on 2015-09-22: Benzinga's Top Initiations

Financial news for HALO dated on 2015-09-22: Barclays Initiates Coverage on Halozyme Therapeutics at Overweight, Announces \$27.00 PT

Financial news for HALO dated on 2015-08-24: Halozyme Therapeutics CFO Stelzer Buys 10,000 Shares @\$17.24/Share -Form 4

Financial news for HALO dated on 2015-08-24: Halozyme Names Michael Labarre as Chief Scientific Officer

Financial news for HALO dated on 2015-08-13: Jim Cramer Advises His Viewers On Halozyme Therapeutics, CF Industries And Tower International

Financial news for HALO dated on 2015-08-10: Halozyme Raises FY15 Sales Outlook from \$85M-\$95M to \$110M-\$115M vs \$95.7M Est.

Financial news for HALO dated on 2015-08-10: Halozyme Reports Q2 EPS \$0.02 vs Loss of \$0.09/Share Est., Sales \$43.4M

Financial news for HALO dated on 2015-08-06: UCSF To Study Halozyme PEGPH20 In Pancreatic Cancer Patients Who Are Candidates For Potentially Curative Surgery

Financial news for HALO dated on 2015-07-31: Eisai, Halozyme Agree To Collaboration On Eribulin & PEGPH20 Metastatic Breast Cancer Investigation

Financial news for HALO dated on 2015-07-31: US Stock Futures Edge Lower Ahead Of Consumer Sentiment Report

Financial news for HALO dated on 2015-07-31: Eisai, Halozyme Anounce Collaboration to Investigate Eribulin and Pegph20 in Advanced Breast Cancer

Financial news for HALO dated on 2015-06-08: Stocks Hitting 52-Week Highs

Financial news for HALO dated on 2015-06-05: Schneider Electric Expands Its Partnership With OpenText To Enable Global Supply Chain Platform

Financial news for HALO dated on 2015-06-05: Halozyme Announces CFO David Ramsay to Retire This Summer, Laurie Stelzer Named as Replacement

Financial news for HALO dated on 2015-06-04: JMP Securities Boosts Halozyme Price Target On 'Long-Term Value'

Financial news for HALO dated on 2015-06-03: Halozyme, AbbVie Enter Global Partnership And Licensing Agreement; Halozyme To Receive One Time \$23M Payment Followed By Milestone Payments Up To \$130M

Financial news for HALO dated on 2015-05-31: Halozyme Presents Promising Phase 2 Findings from Clinical Study of PEGPH20 for Metastatic Pancreatic Cancer Patients

Financial news for HALO dated on 2015-05-27: Halozyme, Ventana Enter Into Global Agreement To Collaboratively Develop Companion Diagnostic For Cancer Treatment

Financial news for HALO dated on 2015-05-18: New Drug Could Transform Pancreatic Cancer Treatment

Financial news for HALO dated on 2015-05-11: Halozyme Therapeutics Reports Q1 Loss of \$0.12/Share vs Loss of \$0.13/Share Est., Sales \$18.666M vs \$19.4M Est.

Financial news for HALO dated on 2015-04-20: Halozyme Issues New Preclinical Data at ASCO: PEGPH20 Boosted T-Cell Access to Tumor Cells in Animals

Financial news for HALO dated on 2015-04-13: Halozyme Therapeutics Names Harry Leonhardt General Counsel, COO

Financial news for HALO dated on 2015-04-08: MLV: We're Reiterating A Buy On Halozyme

Financial news for HALO dated on 2015-04-08: Halozyme Therapeutics Spikes Up Following FDA News

Financial news for HALO dated on 2015-04-08: Halozyme Offers Update Following Type B FDA Meeting: Says Will Proceed with Phase 3 PEGPH20, Expecting Commencement of Phase 3 Study By End of Q1'16

Financial news for HALO dated on 2015-03-23: Halozyme Therapeutics Names James Mazzola VP, Corporate Communications And Investor Relations

Financial news for HALO dated on 2015-03-10: Halozyme Therapeutics Reports First Product Candidate Selection Under Janssen Collaboration

Financial news for HALO dated on 2015-03-02: Halozyme Therapeutics Beats Q4 Views; Outlook Shy Of Consensus

Financial news for HALO dated on 2015-03-02: Halozyme Therapeutics Reports Q4 EPS -\$0.04 Vs Est -\$0.07, Sales \$30.4M Vs Est \$25.59M

Financial news for HALO dated on 2015-02-17: Halozyme Preclinical Study Results of PEGPH20 Published In Molecular Cancer Therapeutics

Financial news for HALO dated on 2015-01-12: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2

Financial news for HALO dated on 2015-01-12: Halozyme Reports Update on Anticipated Milestones: Currently Evaluating, Advancing Investigational PEGPH20; Expecting FY Sales \$85-\$95M

Financial news for HALO dated on 2015-01-08: Benzinga's Volume Movers

Financial news for HALO dated on 2015-01-08: UPDATE: MLV & Co Raises PT On Halozyme Therapeutics On Promising Start To 2015

Financial news for HALO dated on 2015-01-07: UPDATE: Halozyme Shares Rise 27% on Day of Investor, Analyst Meeting

Financial news for HALO dated on 2015-01-07: Halozyme Closes In On A Breakout: A Technical Analysis

Financial news for HALO dated on 2015-01-07: Halozyme Provides Agenda Highlights For Analyst And Investor Meeting

Financial news for HALO dated on 2015-01-06: What Investors Are Looking For After Seeing Unusual Options Activity In Halozyme

Financial news for HALO dated on 2015-01-05: Option Alert: Halozyme Jan \$11 Call; 2,000 Contract Trade at Ask @\$0.25; Currently \$10.08

Financial news for HALO dated on 2014-12-24: Benzinga's Top Initiations

Financial news for HALO dated on 2014-12-24: MLV & Co Initiates Halozyme Therapeutics With Buy

Financial news for HALO dated on 2014-12-24: US Stock Futures Edge Higher; Jobless Claims Data In Focus

Financial news for HALO dated on 2014-12-24: MLV & Co. Initiates Coverage on Halozyme Therapeutics at Buy, Announces \$12.00 PT

Financial news for HALO dated on 2014-12-19: Halozyme Receives European Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20

Financial news for HALO dated on 2014-12-17: Halozyme Announces Global Collaboration with J&J's Janssen for Development, Commercialization of Subcutaneous Products Using ENHANZE Technology

Financial news for HALO dated on 2014-12-12: Halozyme Announces Presentations Of Preclinical Data At The San Antonio Breast Cancer Symposium Annual Meeting

Financial news for HALO dated on 2014-11-10: Halozyme Therapeutics Plummets On Q3 Losses

Financial news for HALO dated on 2014-11-10: Flash: Afterhour Movers: LLNW up 8%; HALO down 14.16%;

Financial news for HALO dated on 2014-11-10: Halozyme Therapeutics, Inc. Reports Q3 EPS of \$(0.16) vs \$(0.14) Est; Revenue of \$14.60M vs \$16.45M Est

Financial news for HALO dated on 2014-11-10: Earnings Scheduled For November 10, 2014

Financial news for HALO dated on 2014-10-24: 8-K from Halozyme Shows VP, General Counsel, Secretary Jean Liu Resigned

Financial news for HALO dated on 2014-10-20: Baxter Reports Launch of HYQVIA in US for Adults with Primary Immunodeficiency

Financial news for HALO dated on 2014-10-20: Halozyme Receives FDA Approval For Additional Manufacturing Facilities For Hylenex Recombinant

Financial news for HALO dated on 2014-10-07: Halozyme Announces Issuance Of U.S. Patent For Companion Diagnostic For PEGPH20

Financial news for HALO dated on 2014-10-03: UPDATE: Halozyme Receives Orphan Drug Designation For Pancreatic Cancer Treatment

Financial news for HALO dated on 2014-10-03: Halozyme Receives Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer

Financial news for HALO dated on 2014-10-02: Halozyme Wins Orphan Drug Designation for Pancreatic Cancer Treatment

Financial news for HALO dated on 2014-09-18: Halozyme Announces SWOG Will Resume Clinical Trial of PEGPH20 In Combo with Modified FOLFIRINOX for Advanced Pancreatic Cancer

Financial news for HALO dated on 2014-09-15: Morning Market Movers

Financial news for HALO dated on 2014-09-15: Benzinga's Top #PreMarket Gainers

Financial news for HALO dated on 2014-09-15: Halozyme Shares Rise 9% Premarket Following FDA Approval of HYQVIA

Financial news for HALO dated on 2014-09-03: Halozyme's PEGPH20 Program In Metastatic Pancreatic Cancer Receives Fast Track Designation

Financial news for HALO dated on 2014-08-11: Halozyme Therapeutics, Inc. Reports Q2 EPS of \$(0.13) vs \$(0.14) Est

Financial news for HALO dated on 2014-07-31: Halozyme Therapeutics Receives Favorable FDA Decision

Financial news for HALO dated on 2014-07-31: Shares of Halozyme Resume Trade, Stock Now Up 10.3%

Financial news for HALO dated on 2014-07-31: PREVIEW: Halozyme Therapeutics to Resume Trading at 2:25 PM ET

Financial news for HALO dated on 2014-07-31: FDA Advisory Committee Panel Provides Favorable Recommendation on Baxter's Hyqvia for Primary Immunodeficiency; Expects FDA Response In Q3

Financial news for HALO dated on 2014-07-31: Halozyme Shares Halted News Pending

Financial news for HALO dated on 2014-07-22: Halozyme Announces Resumption of Patient Enrollment, Dosing in PEGPH20 Clinical Trial

Financial news for HALO dated on 2014-07-11: Benzinga's Top Initiations

Financial news for HALO dated on 2014-07-11: JP Morgan Initiates Halozyme Therapeutics With Outperform

Financial news for HALO dated on 2014-07-11: JP Morgan Initiates Coverage on Halozyme Therapeutics, Inc. at Outperform, Announces \$13.00 PT

Financial news for HALO dated on 2014-06-25: Benzinga's Top #PreMarket Gainers

Financial news for HALO dated on 2014-06-25: Halozyme Announces Commercial Launch of Roche's MabThera SC Triggers Milestone Payment, Co. Will Receive \$5M

Financial news for HALO dated on 2014-06-11: UBS Upgrades Halozyme Therapeutics, Inc. to Buy

Financial news for HALO dated on 2014-06-05: Mid-Day Market Update: US Stocks Surge; PVH Shares Slip On Downbeat Results

Financial news for HALO dated on 2014-06-05: Shares Of Halozyme Up 14% Following FDA Removal Of Hold On PEGPH20

Financial news for HALO dated on 2014-06-05: Morning Market Movers

Financial news for HALO dated on 2014-06-05: Benzinga's Top #PreMarket Gainers

Financial news for HALO dated on 2014-06-04: Halozyme Announces Will Resume PEGPH20 in Pancreatic Cancer

Financial news for HALO dated on 2014-05-29: Option Alert: Halozyme Sep \$12 Call; 1,000 Contracts Traded vs 400 OI; Currently \$8.20

Financial news for HALO dated on 2014-05-13: Mid-Afternoon Market Update: Markets Trade In Choppy Session As Elizabeth Arden Shares Remain Down

Financial news for HALO dated on 2014-05-13: Mid-Day Movers: GORO, HALO, COCO, UEC, EVDY Moving Higher; RDEN, CALL, DXPE, FTEK Lower

Financial news for HALO dated on 2014-05-13: Mid-Day Market Update: Rackspace Gains On Upbeat Earnings; DXP Enterprises Shares Slip

Financial news for HALO dated on 2014-05-13: Mid-Morning Market Update: Markets Gain; Elizabeth Arden To Explore Strategic Alternatives

Financial news for HALO dated on 2014-05-13: Morning Market Movers

Financial news for HALO dated on 2014-05-13: Benzinga's Top #PreMarket Gainers

Financial news for HALO dated on 2014-05-12: Halozyme Therapeutics, Inc. Reports Q1 EPS of \$(0.22) vs \$(0.14) Est

Financial news for HALO dated on 2014-04-15: Mid-Morning Market Update: Markets Gain; Johnson & Johnson Profit Beats Street View

Financial news for HALO dated on 2014-04-15: Morning Market Movers

Financial news for HALO dated on 2014-04-15: Benzinga's Top #PreMarket Gainers

Financial news for HALO dated on 2014-04-15: Benzinga's Top Initiations

Financial news for HALO dated on 2014-04-15: Citigroup Initiates Coverage on Halozyme Therapeutics, Inc. at Buy, Announces \$12.00 PT

Financial news for HALO dated on 2014-04-14: Markets Falling? Get Your Defense Ready

Financial news for HALO dated on 2014-04-09: Morning Market Losers

Financial news for HALO dated on 2014-04-09: Benzinga's Top #PreMarket Losers

Financial news for HALO dated on 2014-04-09: UPDATE: Halozyme Reports Clinical Hold of PEGPH20 Pancreatic Cancer Trial Amid Voluntary Halt

Financial news for HALO dated on 2014-04-09: Halozyme Reports Clinical Hold of PEGPH20 Pancreatic Cancer Trial Amid Voluntary Halt

Financial news for HALO dated on 2014-04-08: Biotechs Struggling To Find A Bottom

Financial news for HALO dated on 2014-04-08: Halozyme Announces Preclinical Data Presentations At The Association Of Cancer Research Annual Meeting

Financial news for HALO dated on 2014-04-04: Market Wrap For April 4: Dow Suffers Triple Digit Point Loss, Nasdaq Continues To Underperform

Financial news for HALO dated on 2014-04-04: Mid-Afternoon Market Update: Markets Drop, Lead Lower by NASDAQ Momentum Names

Financial news for HALO dated on 2014-04-04: Mid-Day Market Update: NASDAQ Tumbles 1.8%; SYNEX Shares Gain After Upbeat Results

Financial news for HALO dated on 2014-04-04: Mid-Morning Market Update: Markets Mixed; CarMax Results Miss Estimates



Financial news for HALO dated on 2014-04-04: Benzinga's Top #PreMarket Losers

Financial news for HALO dated on 2014-04-04: UPDATE: Halozyme Announces Temporary Halt of Phase 2 Trial Enrollment

Financial news for HALO dated on 2014-04-04: Halozyme Announces Temporary Halt of Phase 2 Trial Enrollment

Financial news for HALO dated on 2014-04-03: Form 8-K from Halozyme Shows' Co.'s VP, Commercial Chief James Shaffer Has Resigned

Financial news for HALO dated on 2014-04-02: Halozyme Names Sunil Joshi as VP, Global Product Team Lead for PEGPH20, Oncology

Financial news for HALO dated on 2014-03-31: Mid-Morning Market Update: Markets Open Higher; UTi Worldwide Reports Q4 Loss

Financial news for HALO dated on 2014-03-31: Morning Market Movers

Financial news for HALO dated on 2014-03-31: Halozyme Consistent 1 Trial Of Hylenex(R) Recombinant Met Primary Endpoint

Financial news for HALO dated on 2014-03-28: Halozyme Announces Roche Marketing Authorization of MabThera SC For Patients With Common Forms Of Non-Hodgkin Lymphoma In EU

Financial news for HALO dated on 2014-03-25: Halozyme Announces Positive Results from Phase 1/2 Clinical Trial in Cellulite with HTI-501

Financial news for HALO dated on 2014-02-28: Mid-Afternoon Market Update: Markets Take a Sharp Dip to the Downside, as Traders Take Month-End Profits

Financial news for HALO dated on 2014-02-28: Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE Moving Higher, ELGX, DECK, MDVN, CGEN, ARNA Low

Financial news for HALO dated on 2014-02-27: Halozyme Therapeutics, Inc. Reports Q4 EPS of \$(0.19) vs \$(0.17) Est

Financial news for HALO dated on 2014-02-10: Halozyme Therapeutics Announces Public Offering of ~8.846M Shares

Financial news for HALO dated on 2014-02-04: Halozyme Therapeutics Prices 7.692M Share Offering at \$13.00/Share

Financial news for HALO dated on 2014-02-03: Halozyme Therapeutics Plans \$100M Public Offering

Financial news for HALO dated on 2014-01-24: Halozyme Announces Positive Opinion From CHMP for Roche's MabThera SC

Financial news for HALO dated on 2014-01-03: Form 8-K from Halozyme Shows Amended Credit Pact, Extends Original Loans, Provides Added \$20M in Liquidity

Financial news for HALO dated on 2013-12-18: UPDATE: Halozyme Spikes Higher on Positive CNBC Comments

Financial news for HALO dated on 2013-12-18: Halozyme Spikes Higher

Financial news for HALO dated on 2013-12-18: Option Alert: Halozyme January \$15 Call; 6,010 Contracts Traded Wednesday vs 279 Open Interest; Currently \$13.14

Financial news for HALO dated on 2013-12-02: Baxter Submits Amended BLA to FDA for Hyqvia for Primary Immunodeficiency, Baxter, Halozyme Expecting Six-Month Review

Financial news for HALO dated on 2013-11-08: Halozyme Spikes to High

Financial news for HALO dated on 2013-10-16: Option Alert; Halozyme Therapeutics December 12 Call; 2,138 Contracts Traded @\$1.17; Currently \$11.37

Financial news for HALO dated on 2013-09-26: Halozyme Receives Milestone Payment of \$10M from Roche Following Commercial Launch of Herceptin SC

Financial news for HALO dated on 2013-09-02: Halozyme Announces Roche Receives Marketing Authorization for Herceptin SC in EU

Financial news for HALO dated on 2013-08-07: Halozyme Therapeutics, Inc. Reports Q2 EPS of \$(0.20) vs \$(0.13) Est

Financial news for HALO dated on 2013-08-02: Barclays Downgrades Halozyme Therapeutics, Inc. to Equalweight, Lowers PT to \$8.00

Financial news for HALO dated on 2013-08-01: Benzinga Market Wrap for Thursday, August 1: Record Highs!

Financial news for HALO dated on 2013-08-01: Mid-Afternoon Market Update: Trulia Rises as Hanger Drops on its Second-Quarter Results

Financial news for HALO dated on 2013-08-01: Mid-Day Market Update: Yelp Surges On Narrower Loss, SunPower Shares Decline

Financial news for HALO dated on 2013-08-01: Mid-Morning Market Update: Markets Rally, Procter & Gamble Earnings Top Estimates

Financial news for HALO dated on 2013-08-01: Halozyme Issued Update on ViroPharma Phase 2 Trial of C1 Esterase Inhibitor Formulation with rHuPH20

Financial news for HALO dated on 2013-08-01: Benzinga's Top Pre-Market Losers

Financial news for HALO dated on 2013-07-05: Edison Investment Research Comments on Halozyme Therapeutics on Multiple Value Drivers

Financial news for HALO dated on 2013-07-02: BMO Says Biotech Sector Could See Upside from M&A, Offers Multiple Attractive Targets

Financial news for HALO dated on 2013-06-30: Halozyme Presents Positive Phase 2 HTI-501 Data

Financial news for HALO dated on 2013-06-28: Afternoon Market Gainers

Financial news for HALO dated on 2013-06-28: Halozyme Spikes Higher

Financial news for HALO dated on 2013-06-28: Halozyme Announces Positive Opinion from CHMP on Roche's Herceptin SC for European Approval

Financial news for HALO dated on 2013-06-28: Halozyme Therapeutics Announces Positive Opinion from CHMP On Roche's Herceptin SC for European Approval

Financial news for HALO dated on 2013-05-23: Option Alert: Halozyme Therapeutics July 10 Call; Block Trade: 4,500 Contracts @\$0.30, Currently \$7.03

Financial news for HALO dated on 2013-05-23: Halozyme Names David Ramsay CFO

Financial news for HALO dated on 2013-05-16: Mid-Afternoon Market Update: Optimer Falls as Halozyme Rockets Upwards

Financial news for HALO dated on 2013-05-16: Mid-Day Market Update: US Stocks Fluctuate, Cisco Systems Up on Better-than-Expected Earnings

Financial news for HALO dated on 2013-05-16: Mid-Morning Market Update: Housing Starts Plummet, Initial Jobless Claims Rise

Financial news for HALO dated on 2013-05-15: UPDATE: Piper Jaffray Initiates Halozyme Therapeutics at Overweight on Potential Value Drivers

Financial news for HALO dated on 2013-05-14: Piper Jaffray Initiates Coverage on Halozyme Therapeutics, Inc. at Overweight, Announces \$10.00 PT

Financial news for HALO dated on 2013-05-08: Halozyme Therapeutics, Inc. Reports Q1 EPS of \$(0.17) vs \$(0.15) Est; Revenue of \$11.80M vs \$7.05M Est

Financial news for HALO dated on 2013-05-01: UBS Maintains Neutral on Halozyme Therapeutics, Inc., Lowers PT to \$6.50

Financial news for HALO dated on 2013-03-28: Halozyme Names Matt Posard to Board

Financial news for HALO dated on 2013-03-23: Moves in Smaller Health Care Stocks (ANAC, HALO, PBYI, QCOR)

Financial news for HALO dated on 2013-03-22: Market Wrap for Friday, March 22: Stocks Rise on Hopes of Bailout Deal for Cyprus

Financial news for HALO dated on 2013-03-22: Mid-Day Market Update: Micron Surges On Upbeat Revenue, Informatica Declines

Financial news for HALO dated on 2013-03-22: Baxter and Halozyme Announce Positive Opinion for HyQvia for Treatment of Primary and Secondary Immunodeficiencies in the European Union

Financial news for HALO dated on 2013-03-11: Option Alert: Halozyme Therapeutics June 7.5 Call; Block Trade: 4,200 Contracts Traded @\$0.65, Currently \$5.98

Financial news for HALO dated on 2013-02-01: UPDATE: BMO Capital Markets Reiterates Outperform Rating, Lowers PT on Halozyme Therapeutics

Financial news for HALO dated on 2013-02-01: BMO Capital Maintains Outperform on Halozyme Therapeutics, Inc., Lowers PT to \$9.00

Financial news for HALO dated on 2013-01-30: Halozyme Therapeutics Spikes to Lows

Financial news for HALO dated on 2013-01-30: Wedbush Downgrades Halozyme Therapeutics, Inc. to Neutral, Lowers PT to \$13.00

Financial news for HALO dated on 2013-01-30: Jefferies Reiterates Underperform Rating, \$4 PT on Halozyme Therapeutics

Financial news for HALO dated on 2013-01-15: One Biotech Stock Investors are Unfairly Ignoring

Financial news for HALO dated on 2013-01-14: Mid-Afternoon Market Update: Herbalife Rises Above Ackman's Top, SunPower Remains Down

Financial news for HALO dated on 2013-01-14: UPDATE: BMO Capital Markets Upgrades Halozyme Therapeutics to Outperform, Raises PT

Financial news for HALO dated on 2013-01-14: BMO Capital Upgrades Halozyme Therapeutics, Inc. to Outperform, Raises to \$12.00

Financial news for HALO dated on 2013-01-07: Halozyme Sees 2013 Cash Burn \$45-50M, Cash Balance ~\$100M

Financial news for HALO dated on 2012-12-21: Halozyme Soars After Announcing Deal With Pfizer

Financial news for HALO dated on 2012-12-21: Mid-Afternoon Update: Herbalife Takes a Bigger Beating, Markets Still Red

Financial news for HALO dated on 2012-12-21: Benzinga's Top Pre-Market Gainers

Financial news for HALO dated on 2012-12-21: UPDATE: Halozyme Shares Now Up ~18% Following Resumption

Financial news for HALO dated on 2012-12-21: Shares of Halozyme Resume Trading Up ~4%

Financial news for HALO dated on 2012-12-21: PREVIEW: Halozyme Therapeutics to Resume Trading at 8:05 AM ET

Financial news for HALO dated on 2012-12-21: Halozyme Therapeutics, Pfizer Collaborate to Develop And Commercialize Subcutaneous Biologics

Financial news for HALO dated on 2012-12-21: Halozyme Halted; Pending News

Financial news for HALO dated on 2012-12-08: Halozyme Announces Roche Filing to European Medicines Agency Triggers \$4M Milestone Payment

Financial news for HALO dated on 2012-11-09: Barclays Maintains Halozyme Therapeutics at Overweight, Lowers PT from \$10 to \$9

Financial news for HALO dated on 2012-11-08: Halozyme Therapeutics Reports Q3 EPS \$-0.18 vs \$-0.14 Est; Revenues \$5.3M vs \$6.09M Est

Financial news for HALO dated on 2012-10-08: Wedbush Securities Maintains Halozyme Therapeutics at Outperform, Raises PT from \$13 to \$17

Financial news for HALO dated on 2012-10-08: Hearing Wedbush Raises PT on Halozyme to \$17; Remains on Best Ideas List

Financial news for HALO dated on 2012-09-27: UBS Initiates Coverage on Halozyme Therapeutics at Neutral, Announces PT of \$8

Financial news for HALO dated on 2012-09-26: Benzinga's M&A Chatter for Wednesday September 26, 2012

Financial news for HALO dated on 2012-09-24: Barclays Maintains Halozyme Therapeutics at Overweight, Raises PT from \$8 to \$10

Financial news for HALO dated on 2012-09-24: Jefferies & Company Maintains Halozyme

Therapeutics at Underperform, Raises PT from \$3 to \$4

Financial news for HALO dated on 2012-09-21: Benzinga Mid-Afternoon Market Update

Financial news for HALO dated on 2012-09-21: Jefferies & Company Maintains Halozyme Therapeutics at Underperform, Raises PT from \$3 to \$4

Financial news for HALO dated on 2012-09-21: Benzinga Mid-Day Market Update

Financial news for HALO dated on 2012-09-21: Benzinga Mid-Morning Market Update

Financial news for HALO dated on 2012-09-21: ViroPharma, Halozyme Resume Trading

Financial news for HALO dated on 2012-09-21: PREVIEW: ViroPharma, Halozyme to Resume Trading at 7:30am

Financial news for HALO dated on 2012-09-21: ViroPharma And Halozyme Provide Update On Clinical Development Of Subcutaneous Cinryze(r) (C1 Esterase Inhibitor [Human]) With Recombinant Human Hyaluronidase (rHuPH20)

Financial news for HALO dated on 2012-09-21: ViroPharma, Halozyme Therapeutics Halted on FDA News

Financial news for HALO dated on 2012-09-06: Halozyme Spokesperson Says Can't Speculate on What's Driving Trading

Financial news for HALO dated on 2012-09-06: Option Alert: Halozyme Call Volume at 1,425% of Average; Currently \$6.10

Financial news for HALO dated on 2012-08-06: Halozyme Therapeutics Reports Q2 EPS \$-13 vs \$-0.15 Est; Revenues \$7.76M vs \$5.22M Est

Financial news for HALO dated on 2012-08-02: Barclays Maintains Halozyme Therapeutics at Overweight, Lowers PT from \$15 to \$8

Financial news for HALO dated on 2012-08-02: UPDATE: Jefferies Downgrades Halozyme Therapeutics to Underperform on FDA Headwinds

Financial news for HALO dated on 2012-08-02: Jefferies & Company Downgrades Halozyme Therapeutics from Hold to Underperform, Lowers PT from \$8 to \$3

Financial news for HALO dated on 2012-08-01: Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA

Financial news for HALO dated on 2012-06-11: Halozyme's Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes

Financial news for HALO dated on 2012-06-11: Wedbush Reiterates Outperform Rating for Halozyme Therapeutics

Financial news for HALO dated on 2012-06-11: Wedbush Reiterates Outperform and Best Idea Rating on Halozyme Therapeutics

Financial news for HALO dated on 2012-06-06: Option Alert: Halozyme Therapeutics June 10 Call; Block Trade: 4,700 Contracts; Currently \$8.41

Financial news for HALO dated on 2012-05-07: Halozyme Therapeutics Reports Q1 EPS \$-0.14 vs \$-0.11 Est; Revenues \$7.4M vs \$7.31M Est

Financial news for HALO dated on 2012-04-17: Wedbush: FDA Undisclosed Concerns; Halozyme Therapeutics FV Reduced

Financial news for HALO dated on 2012-04-17: UPDATE: Jefferies Cuts PT to \$8 on Halozyme Therapeutics

Financial news for HALO dated on 2012-04-17: Wedbush Securities Maintains Halozyme Therapeutics at Outperform, Lowers PT from \$17 to \$16

Financial news for HALO dated on 2012-04-17: Jefferies & Company Maintains Halozyme Therapeutics at Hold, Lowers PT from \$10 to \$8

Financial news for HALO dated on 2012-04-17: Jefferies & Company Maintains Halozyme Therapeutics at Hold, Lowers PT from \$10 to \$8

Financial news for HALO dated on 2012-04-16: Brean Murray Carret & Co. Maintains Halozyme Therapeutics at Buy, Lowers PT from \$13 to \$11

Financial news for HALO dated on 2012-04-16: Morning Market Losers

Financial news for HALO dated on 2012-04-16: Halozyme Therapeutics Resumes Trading

Financial news for HALO dated on 2012-04-16: PREVIEW: Halozyme Therapeutics to Resume Trading at 8:30am

Financial news for HALO dated on 2012-04-16: Baxter and Halozyme Provide Update on HyQ Biologics License Application

Financial news for HALO dated on 2012-04-16: Halozyme Therapeutics Halted for Pending News

Financial news for HALO dated on 2012-04-10: Financial Breakfast: Morning News Summary for April 10, 2012

Financial news for HALO dated on 2012-04-10: Benzinga's Top Downgrades

Financial news for HALO dated on 2012-04-10: UPDATE: Jefferies Downgrades Halozyme Therapeutics to Hold

Financial news for HALO dated on 2012-04-10: Jefferies & Company Downgrades Halozyme Therapeutics from Buy to Hold, Maintains PT at \$10

Financial news for HALO dated on 2012-03-12: Oppenheimer Anticipating FDA Approval of HyQvia

Financial news for HALO dated on 2012-03-09: Earnings Scheduled For March 9

Financial news for HALO dated on 2012-03-06: ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze with Recombinant Human Hyaluronidase

Financial news for HALO dated on 2012-02-10: Halozyme Announces Pricing of 6.8M Share Public Offering at \$10.61

Financial news for HALO dated on 2012-02-09: Halozyme Announces Proposed Public Offering of Common Stock; 6.8M Shares

Financial news for HALO dated on 2012-01-31: Halozyme Therapeutics Announces HTI-501 Data Support Commencement of Phase 2 Portion of Clinical Trial

Financial news for HALO dated on 2011-12-11: Weekly Homework: In Search Of The Santa Claus Rally (w/ Economic Calendar & Stock Radar)

Financial news for HALO dated on 2011-12-07: Wedbush Reiterates Outperform, \$17 PT On Halozyme Therapeutics

Financial news for HALO dated on 2011-12-06: ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze

Financial news for HALO dated on 2011-11-09: UPDATE: Wedbush Raises Price Target on Halozyme to \$17

Financial news for HALO dated on 2011-11-09: Wedbush Raises PT on Halozyme to \$17, Adds to Best Ideas List

Financial news for HALO dated on 2011-10-27: Halozyme Therapeutics Announces Positive Results from Enzyme-Augmented Insulin Pump Trial

Financial news for HALO dated on 2011-10-24: Notable Call Options Activity in Halozyme Therapeutics

Financial news for HALO dated on 2011-10-21: Oppenheimer Outperform on Halozyme Therapeutics

Financial news for HALO dated on 2011-10-21: Halozyme Announces Positive Results From Phase 2 Ultrafast Insulin Trials in Patients with Type 1 and Type 2 Diabetes

Financial news for HALO dated on 2011-10-18: End-of-Day Market Summary for October 18, 2011

Financial news for HALO dated on 2011-10-18: Afternoon Gainers; Housing Stocks up on Upbeat NAHB Data

Financial news for HALO dated on 2011-10-18: UPDATE: Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial

Financial news for HALO dated on 2011-10-05: Halozyme Begins Randomized, Controlled Clinical Trial with PEGPH20 in Patients with Advanced Pancreatic Cancer

Financial news for HALO dated on 2011-09-28: Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy

Financial news for HALO dated on 2011-09-13: ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze

Financial news for HALO dated on 2011-07-08: Baxter and Halozyme Announce Top-Line Results of Phase III Study of HyQ in Patients with Primary Immunodeficiency

Financial news for HALO dated on 2011-05-11: Morning News Summary For May 11, 2011

Financial news for HALO dated on 2011-05-11: Benzinga's Top Pre-Market NASDAQ Gainers (ROVI, ASYS, ZAGG, HALO)

Financial news for HALO dated on 2011-05-11: Halozyme Therapeutics and ViroPharma Announce \$83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze

Financial news for HALO dated on 2011-04-01: Stifel Nicolaus Initiates Coverage on Halozyme Thearapeutics at Buy (HALO)

Financial news for HALO dated on 2011-03-23: Wedbush Says HALO Is "No Fallen Angel"

Financial news for HALO dated on 2011-03-11: Halozyme Therapeutics Reports Q4 EPS of \$(0.17) vs. \$(0.12)

Financial news for HALO dated on 2011-03-11: Earnings Scheduled For March 11 (AWR, HIBB, BIOS, ANN, ARNA, LMIA, HALO, UTSI, PKT, NGPC, SNTA)

Financial news for HALO dated on 2011-03-04: Halozyme Therapeutics to Host Q4 and 2010 Financial Results Conference Call on March 11

Financial news for HALO dated on 2010-12-03: Halozyme Therapeutics CEO, President Resigns

Financial news for HALO dated on 2010-11-08: Jefferies Has Note On Halozyme Therapeutics (HALO)

Financial news for HALO dated on 2010-11-05: Halozyme Therapeutics Reports Third Quarter EPS of \$(0.13)

Financial news for HALO dated on 2010-11-04: A Peek Into The Market Before The Trading Starts

Financial news for HALO dated on 2010-11-04: Halozyme Therapeutics Awarded Four Qualifying Therapeutic Discovery Project Grants

Financial news for HALO dated on 2010-10-15: Halozyme Reveals New Development Plans

Financial news for HALO dated on 2010-10-15: Halozyme Partners With Ph3 Products In Product Development

Financial news for HALO dated on 2010-10-11: Halozyme Therapeutics To Cut 25% of Its Workforce (HALO)

Financial news for HALO dated on 2010-10-11: Halozyme Therapeutics Announces Implementation of Development Strategy

Financial news for HALO dated on 2010-09-09: A Peek Into The Market Before The Trading Starts

Financial news for HALO dated on 2010-09-09: Halozyme Therapeutics Announces Pricing of Public Offering

Financial news for HALO dated on 2010-09-08: Halozyme Therapeutics Announces Public Offering of 8.3 Million Shares

Financial news for HALO dated on 2010-08-09: Jefferies Reiterates Buy On Halozyme Therapeutics After In-Line 2Q Loss (HALO)

Financial news for HALO dated on 2010-06-29: 6-29-10 Daily Small Cap Market News and Stock Highlights from SmallCapVoice.com

Financial news for HALO dated on 2010-06-07: Drug Recall to Negatively Impact Halozyme: Retains 'Outperform' Rating At Oppenheimer (HALO)

Financial news for HALO dated on 2010-05-17: Halozyme Announces Recall

Financial news for HALO dated on 2010-05-17: Halozyme Announces Recall

Financial news for HALO dated on 2010-04-08: Phase III Development Of Drug Candidates By HALO To Boost Shareholder Value

Financial news for HALO dated on 2010-03-22: Benzinga's Top Upgrades (UNFI, AGP, HALO, PPS, FSP)

Financial news for HALO dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?

Financial news for HALO dated on 2010-03-12: Benzinga's News Roundup (HALO, LACO, ANN, ARNA)

Financial news for HALO dated on 2010-03-02: Monday's Hot Stocks: Charge Up Your Portfolio With Volterra

Financial news for HALO dated on 2009-08-12: TSX Venture Exchange Daily Bulletins for August 12, 2009